This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lenaerts, A. J. M.
Right arrow Articles by Orme, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lenaerts, A. J. M.
Right arrow Articles by Orme, I. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 783-785, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.783-785.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Rapid In Vivo Screening of Experimental Drugs for Tuberculosis Using Gamma Interferon Gene-Disrupted Mice

Anne J. M. Lenaerts,* Veronica Gruppo, Jason V. Brooks, and Ian M. Orme

Department of Microbiology, Colorado State University, Fort Collins, Colorado 80523

Received 27 August 2002/ Returned for modification 21 October 2002/ Accepted 4 November 2002

We have developed a rapid new in vivo method for screening experimental drugs for their activity against Mycobacterium tuberculosis by using the gamma interferon gene-disrupted (GKO) C57BL/6 mouse. Due to the rapid growth of the infection, statistical differences indicating positive efficacy of active compounds can be seen after only 8 days of treatment. To validate this model, several fluoroquinolones, including ciprofloxacin, levofloxacin, moxifloxacin, and gatifloxacin, were tested in parallel.

* Corresponding author. Mailing address: Department of Microbiology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-3079. Fax: (970) 491-5125. E-mail: lenaerts{at}colostate.edu.

Antimicrobial Agents and Chemotherapy, February 2003, p. 783-785, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.783-785.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Woolhiser, L. K., Hoff, D. R., Marietta, K. S., Orme, I. M., Lenaerts, A. J. (2009). Testing of Experimental Compounds in a Relapse Model of Tuberculosis Using Granulocyte-Macrophage Colony-Stimulating Factor Gene-Disrupted Mice. Antimicrob. Agents Chemother. 53: 306-308 [Abstract] [Full Text]  
  • Dharmadhikari, A. S., Nardell, E. A. (2008). What Animal Models Teach Humans about Tuberculosis. Am. J. Respir. Cell Mol. Bio. 39: 503-508 [Abstract] [Full Text]  
  • Villar, R., Vicente, E., Solano, B., Perez-Silanes, S., Aldana, I., Maddry, J. A., Lenaerts, A. J., Franzblau, S. G., Cho, S.-H., Monge, A., Goldman, R. C. (2008). In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother 62: 547-554 [Abstract] [Full Text]  
  • Vicente, E., Villar, R., Burguete, A., Solano, B., Perez-Silanes, S., Aldana, I., Maddry, J. A., Lenaerts, A. J., Franzblau, S. G., Cho, S.-h., Monge, A., Goldman, R. C. (2008). Efficacy of Quinoxaline-2-Carboxylate 1,4-Di-N-Oxide Derivatives in Experimental Tuberculosis. Antimicrob. Agents Chemother. 52: 3321-3326 [Abstract] [Full Text]  
  • Ordway, D., Henao-Tamayo, M., Smith, E., Shanley, C., Harton, M., Troudt, J., Bai, X., Basaraba, R. J., Orme, I. M., Chan, E. D. (2008). Animal model of Mycobacterium abscessus lung infection. J. Leukoc. Biol. 83: 1502-1511 [Abstract] [Full Text]  
  • Lenaerts, A. J., Bitting, C., Woolhiser, L., Gruppo, V., Marietta, K. S., Johnson, C. M., Orme, I. M. (2008). Evaluation of a 2-Pyridone, KRQ-10018, against Mycobacterium tuberculosis In Vitro and In Vivo. Antimicrob. Agents Chemother. 52: 1513-1515 [Abstract] [Full Text]  
  • Gruppo, V., Johnson, C. M., Marietta, K. S., Scherman, H., Zink, E. E., Crick, D. C., Adams, L. B., Orme, I. M., Lenaerts, A. J. (2006). Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis.. Antimicrob. Agents Chemother. 50: 1245-1250 [Abstract] [Full Text]  
  • Nuermberger, E., Tyagi, S., Williams, K. N., Rosenthal, I., Bishai, W. R., Grosset, J. H. (2005). Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am. J. Respir. Crit. Care Med. 172: 1452-1456 [Abstract] [Full Text]  
  • Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., Orme, I. M. (2005). Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models. Antimicrob. Agents Chemother. 49: 2294-2301 [Abstract] [Full Text]  
  • Nikonenko, B. V., Samala, R., Einck, L., Nacy, C. A. (2004). Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48: 4550-4555 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R. J., Vernon, A. A., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 170: 1131-1134 [Abstract] [Full Text]  
  • Shoen, C. M., DeStefano, M. S., Sklaney, M. R., Monica, B. J., Slee, A. M., Cynamon, M. H. (2004). Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. J Antimicrob Chemother 53: 641-645 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
  • Cynamon, M. H., Sklaney, M. (2003). Gatifloxacin and Ethionamide as the Foundation for Therapy of Tuberculosis. Antimicrob. Agents Chemother. 47: 2442-2444 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»